• Home
  1. Home
  2. Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study
Scientific article
English

Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study

Contributors

Young, Jim; De Geest, Sabina; Spirig, Rebecca; Flepp, Markus; Rickenbach, Martin; Furrer, Hansjakob; Bernasconi, Enos; Hirschel, Bernard; Telenti, Amalio; Vernazza, Pietro; Battegay, Manuel; Bucher, H. C.

Published in

BMJ. British medical journal, vol. 328, no. 7430, 15

Publication date

2004

Abstract

OBJECTIVES: To explore the association between a stable partnership and clinical outcome in HIV infected patients receiving highly active antiretroviral therapy (HAART). DESIGN: Prospective cohort study of adults with HIV (Swiss HIV cohort study). SETTING: Seven outpatient clinics throughout Switzerland. PARTICIPANTS: The 3736 patients in the cohort who started HAART before 2002 (median age 36 years, 29% female, median follow up 3.6 years). MAIN OUTCOME MEASURES: Time to AIDS or death (primary endpoint), death alone, increases in CD4 cell count of at least 50 and 100 above baseline, optimal viral suppression (a viral load below 400 copies/ml), and viral rebound. RESULTS: During follow up 2985 (80%) participants reported a stable partnership on at least one occasion. When starting HAART, 52% (545/1042) of participants reported a stable partnership; after five years of follow up 46% (190/412) of participants reported a stable partnership. In an analysis stratified by previous antiretroviral therapy and clinical stage when starting HAART (US Centers for Disease Control and Prevention group A, B, or C), the adjusted hazard ratio for progression to AIDS or death was 0.79 (95% confidence interval 0.63 to 0.98) for participants with a stable partnership compared with those without. Adjusted hazards ratios for other endpoints were 0.59 (0.44 to 0.79) for progression to death, 1.15 (1.06 to 1.24) for an increase in CD4 cells of 100 counts/microl or more, and 1.06 (0.98 to 1.14) for optimal viral suppression. CONCLUSIONS: A stable partnership is associated with a slower rate of progression to AIDS or death in HIV infected patients receiving HAART.

Keywords

  • Acquired Immunodeficiency Syndrome/drug therapy/mortality
  • Adult
  • Antiretroviral Therapy, Highly Active/ mortality
  • Cohort Studies
  • Disease Progression
  • Female
  • HIV Infections/ drug therapy/mortality
  • Humans
  • Interpersonal Relations
  • Male
  • Prospective Studies
  • Sexual Partners
  • Socioeconomic Factors
  • Switzerland/epidemiology

UNIGE affiliation entities

Citation (ISO format)

YOUNG, Jim et al. Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study. In: BMJ. British medical journal, 2004, vol. 328, n° 7430, p. 15. doi: 10.1136/bmj.328.7430.15

Main files (1)

Article

Identifiers

Additional URL for this publication

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC313896/pdf/bmj32800015.pdf

Journal ISSN

0959-8138
574views
0downloads

Technical informations

Creation

21/06/2010 10:27:15

First validation

21/06/2010 10:27:15

Update

14/03/2023 15:46:20

Status update

14/03/2023 15:46:20

Last indexation

29/10/2024 15:22:29
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated